Dice Therapeutics — DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis

14 slides

Dice Therapeutics · Health & Biotech · 2022

About this deck

Explore the presentation slide by slide for its financial analysis, transaction details, and investor communications.

Read moreRead less
Company
Dice Therapeutics
Industry
Health & Biotech
Year
2022
Slides
14
Company
Dice Therapeutics
Industry
Health & Biotech
Year
2022
Slides
14
Dice Therapeutics — DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild-to-moderate psoriasis Investment Banking Pitch Deck | Banker Decks